Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222807 · ClinicalTrials.gov registry record
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 200
- Enrollment target
NCT00222807: Completed study, sponsored by University of Pittsburgh.
NCT00222807 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00222807 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls. Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2003-08 |
| Est. Completion | 2016-03 |
What the finished NCT00222807 record still lists
NCT00222807 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00222807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00222807 about?
NCT00222807 is a clinical study titled "Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus". This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and ...
What is the current status of trial NCT00222807?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2003-08. Estimated completion is 2016-03.
Who is sponsoring clinical trial NCT00222807?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia